January 13th, 2022
Listen now
The FDA is making some changes in the accelerated approval process. In this episode, we’ll discuss the recent changes with the FDA’s regulation of cancer drugs and how these shifts will impact the biopharma industry.   Also in this episode, we cover the week's biggest headlines from the annual J.P. Morgan Healthcare conference.  To learn more about topics in this episode: Fierce JPM Week Podnosis: The Pulse of the Healthcare Industry FDA wants confirmatory trials to be underway before granting accelerated cancer nods, Pazdur says Capitalizing on share price crash, AstraZeneca inks $1.8B CinCor takeover for blood pressure drug JPM23: Chiesi gets jump-start on JPM buzz with $1.48B Amryt buyout JPM23: Ipsen scoops up liver disease specialist Albireo for $952M Editas rewrites its own code after tough 2022, sending staff packing and editing down programs JPM23: Editas touts skinnier pipeline after major shake-up to ride out 'unfriendly' markets With Leqembi approval in Alzheimer's disease, Eisai and Biogen plot 'meticulous' launch AstraZeneca's first-in-class rescue inhaler Airsupra wins FDA nod—but only for adult use Baxter bids adieu to $5B kidney care division with spinout plan "The Top Line" is produced by senior multimedia producer Teresa Carey with managing editor Querida Anderson and senior editors Annalee Armstrong, Ben Adams, Conor Hale and Eric Sagonowsky. The sound engineer is Caleb Hodgson. The stories are by all our “Fierce” journalists. Like and subscribe wherever you listen to your podcasts. See omnystudio.com/listener for privacy information.
More Episodes
This year kicks off the second decade of Fierce Medtech’s annual Fierce 15 report. Not surprisingly, the startups featured on this year’s list are raising the bar for medtech developers everywhere. Staff writer Andrea Park and Editor-in-Chief Ayla Ellison discuss a few of the 15 startups that...
Published 03/24/23
Published 03/19/23
Is it all bad news in the bear market? Not necessarily. After a tumultuous couple of years, many biotechs are looking for signs of improvement in 2023. After all, the biotech sector felt the market pain acutely, particularly over the last 18 months: 2022 marked the longest period of net negative...
Published 03/19/23